pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Eli Lilly and Co · news · pharmadog
← back to Eli Lilly and Co
News mentioning Eli Lilly and Co
71
stories
10h
Roche pours $750M into Oregon manufacturing plant as obesity push expands
biospace
1d
Kolon TissueGene cuts 37 US staffers after Phase 3 fail
biospace
1d
Amylyx’s redemption story, Summit’s survival woes, Definium’s anxiety win, more
biospace
2d
Novo takes first round of oral obesity duel. Can it stay ahead of Lilly?
biospace
2d
Sandoz inks $322M Henlius deal for rights to as many as 10 biosimilars
biospace
2d
Rebounding biotech funds expected to spur CDMO growth within year
biospace
2d
Amylyx’s bet on a GLP-1 blocker pays off
biopharma dive
3d
STAT+: Pharmalittle: We’re reading about an AstraZeneca setback, falling U.S. drug prices, and more
stat
6d
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
biopharma dive
7d
Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale
biospace
8d
Lilly cracks down on black market for obesity asset retatrutide with six lawsuits
biospace
8d
7 companies hiring in North Carolina now
biospace
8d
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
biospace
9d
With tech backing, AI biotechs force biopharma into ‘fail-fast’ drug development
biospace
9d
Amgen lays groundwork for new R&D center in Hyderabad
fiercebiotech
10d
Scribe’s Benjamin Oakes on a rare IPO and bringing CRISPR to the masses
biopharma dive
13d
Why Big Pharma is chasing the industry’s most-powerful supercomputer
biopharma dive
13d
STAT+: Pharmalittle: We’re reading about Replimune’s melanoma drug, a Medicare policy change, and more
stat
14d
The top 12 companies hiring in biopharma now
biospace
15d
Lilly confident in slow and steady Foundayo launch, as ex-US sales shine
biospace
15d
Lilly, FDA retatrutide biologic dispute comes to a head as submission nears
biospace
15d
Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1
biospace
20d
Lilly and Resilience invest $750M in diabetes and obesity drug device supply
biospace
21d
J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B
biopharma dive
22d
Biogen validated the Alzheimer’s tau theory. CEO Viehbacher still isn’t betting the store
biospace
23d
Altimmune rises as GLP-1/glucagon drug curbs heavy drinking in mid-stage study
biospace
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
27d
Lilly’s $3.8B psychedelics bet won’t open the M&A floodgates
biospace
27d
Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
biospace
28d
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
stat
← prev
page 1 of 3
next →
